AGN News and Press, Allergan plc From 09/11/20

As the youngest of the pharma juggernauts, AbbVie (NYSE: ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has built an attractive portfolio of d...

This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 08/14/2020. Please visit our Tracking David Tepper’s Appaloo...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 08/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

Quick Take InMode ( INMD ) went public in August, 2019, selling five million shares at $14.00 to collect $70 million in gross proceeds. The firm has been commercializing its adipose fat tissue remodeling technologies. INMD has managed its business through the Covid-19 pandemic for long...

VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has enr...

The pandemic driven recession isn’t even a speed bump for AbbVie ( ABBV ), a biopharmaceutical giant — and that’s a big deal as this company won’t have to recover, asserts Tom Hutchinson , growth and income expert and editor of Cabot Dividend Investor .  ...

Evolus, Inc. ( EOLS ) is a biotech company that has gained FDA approval for its lead product Jeuveau, which is the only known Neurotoxin dedicated to the aesthetics or more specific treatment of glabellar lines. Ever since the commercial launch, everyone in the aesthetics treatment industry ...

This article is part of a series that provides an ongoing analysis of the changes made to GMO’s 13F stock portfolio on a quarterly basis. It is based on GMO’s regulatory 13F Form filed on 05/14/2020. Jeremy Grantham’s 13F portfolio value decreased ~20%, from $14.97B to $...

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly basis. It is based on Robbins’ regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Larry Robbins’ Glenview Capital Manage...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 05/15/2020. Please visit our Tracking Dan Loeb’s Third Point Portfoli...